These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18069261)

  • 41. Unraveling the multiple myeloma genome in the next-generation sequencing era: challenges to translating knowledge into the clinic.
    Braggio E; Fonseca R
    Expert Rev Hematol; 2011 Dec; 4(6):579-81. PubMed ID: 22077519
    [No Abstract]   [Full Text] [Related]  

  • 42. Massive limb lymphedema as the initial presentation of multiple myeloma: a case report.
    Yang C; You L; Meng H
    Transl Cancer Res; 2021 Mar; 10(3):1599-1602. PubMed ID: 35116485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting NF-κB Signaling for Multiple Myeloma.
    Wong AH; Shin EM; Tergaonkar V; Chng WJ
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32781681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Revealing dynamic regulations and the related key proteins of myeloma-initiating cells by integrating experimental data into a systems biological model.
    Zhang L; Liu G; Kong M; Li T; Wu D; Zhou X; Yang C; Xia L; Yang Z; Chen L
    Bioinformatics; 2021 Jul; 37(11):1554-1561. PubMed ID: 31350562
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Risk stratification and target therapies in multiple myeloma].
    Chen SL
    Zhonghua Nei Ke Za Zhi; 2010 Mar; 49(3):195-7. PubMed ID: 20450647
    [No Abstract]   [Full Text] [Related]  

  • 46. Progress in multiple myeloma.
    Jagannath S
    Clin Lymphoma Myeloma; 2008 Aug; 8(4):202-4. PubMed ID: 18765306
    [No Abstract]   [Full Text] [Related]  

  • 47. From Bench to Bedside: The Evolution of Genomics and Its Implications for the Current and Future Management of Multiple Myeloma.
    Morgan GJ; Boyle EM; Davies FE
    Cancer J; 2021 May-Jun 01; 27(3):213-221. PubMed ID: 34549910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MK2 is a therapeutic target for high-risk multiple myeloma.
    Gu C; Cheng H; Yang H; Bian Y; Wang Y; Zhang Y; Pisano M; Hu G; Yang Y
    Haematologica; 2021 Jun; 106(6):1774-1777. PubMed ID: 29567777
    [No Abstract]   [Full Text] [Related]  

  • 49. Celebrating 25 years of NF-κB.
    Nat Immunol; 2011 Jul; 12(8):681. PubMed ID: 21772274
    [No Abstract]   [Full Text] [Related]  

  • 50. [What is new in the management of multiple myeloma].
    Vrancken L; Muller J; Lejeune M; Gregoire C; Delens L; Jaspers A; Servais S; Prijck B; Baron F; Caers J; Beguin Y
    Rev Med Suisse; 2018 Aug; 14(615):1438-1442. PubMed ID: 30136458
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Urethane treatment for myeloma].
    GEORGESCO M
    Union Med Can; 1956 Oct; 85(10):1172-4. PubMed ID: 13392116
    [No Abstract]   [Full Text] [Related]  

  • 52. PDPK1/RSK2 signaling pathway as the possible therapeutic target for multiple myeloma.
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():180-4. PubMed ID: 30615342
    [No Abstract]   [Full Text] [Related]  

  • 53. Introduction by the Guest Editor: Recent advances in biology and treatment of multiple myeloma.
    Tanaka H
    Int J Hematol; 2020 Apr; 111(4):494-495. PubMed ID: 31984452
    [No Abstract]   [Full Text] [Related]  

  • 54. Genetic mutations and outcome in myeloma.
    Bagcchi S
    Lancet Oncol; 2015 Sep; 16(9):e434. PubMed ID: 26299605
    [No Abstract]   [Full Text] [Related]  

  • 55. [Wnt signal inhibitors against multiple myeloma].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():173-9. PubMed ID: 30615341
    [No Abstract]   [Full Text] [Related]  

  • 56. [Molecular biology of multiple myeloma: introduction].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():87-91. PubMed ID: 30615312
    [No Abstract]   [Full Text] [Related]  

  • 57. [Molecular pathogenesis of myeloma for the therapeutic targets].
    Hanamura I
    Nihon Rinsho; 2007 Dec; 65(12):2202-8. PubMed ID: 18069261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gene mutation revelation points to new target for myeloma treatment, studies say.
    Garber K
    J Natl Cancer Inst; 2007 Sep; 99(18):1362-4. PubMed ID: 17848662
    [No Abstract]   [Full Text] [Related]  

  • 59. TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma).
    Nuñez C; Cansino JR; Bethencourt F; Pérez-Utrilla M; Fraile B; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Royuela M
    Histopathology; 2008 Aug; 53(2):166-76. PubMed ID: 18752500
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of nuclear factor kappaB on angiogenesis regulation through monocyte chemotactic protein-1 in myeloma.
    Stifter S
    Med Hypotheses; 2006; 66(2):384-6. PubMed ID: 16253428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.